ZIOPHARM Oncology Inc (NASDAQ:ZIOP)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $4.27 and last traded at $4.28, with a volume of 2371452 shares changing hands. The stock had previously closed at $4.55.
Several brokerages recently commented on ZIOP. BidaskClub lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $12.58.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. ZIOPHARM Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the firm earned ($0.11) earnings per share. equities analysts expect that ZIOPHARM Oncology Inc will post -0.54 earnings per share for the current year.
In other news, CEO Laurence James Neil Cooper bought 6,440 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares in the company, valued at $5,071,861.08. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.40% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after acquiring an additional 553,933 shares during the period. State Street Corp grew its stake in ZIOPHARM Oncology by 12.8% in the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after acquiring an additional 517,057 shares during the period. Morgan Stanley grew its stake in ZIOPHARM Oncology by 19.5% in the 1st quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after acquiring an additional 324,774 shares during the period. Northern Trust Corp grew its stake in ZIOPHARM Oncology by 10.1% in the 2nd quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock valued at $10,144,000 after acquiring an additional 149,067 shares during the period. Finally, Geode Capital Management LLC grew its stake in ZIOPHARM Oncology by 3.9% in the 1st quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock valued at $6,444,000 after acquiring an additional 38,173 shares during the period. 41.86% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/11/12/ziopharm-oncology-inc-ziop-sets-new-12-month-low-at-4-27.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.